Azadeh Feizpour
@AzadehFeizpour
Followers
107
Following
124
Media
6
Statuses
52
Senior Research Fellow @TheFlorey and @RoweLab_aus. The views are mine alone and do not represent the views of The Florey.
Melbourne, Victoria
Joined December 2016
Proud to see Australian research on sleep and dementia, led by Prof. Sharon Naismith, featured in a #AAIC2025 Plenary. A true flagship in the field. #Dementia #Alzheimers
1
0
4
Thrilled to be back home at @BarcelonaBeta as the Lead of the Neuroimaging Group! 🎉 Even better, we have a PhD position open to work with PET & MRI imaging in early stages of #Alzheimer’s. If you know someone passionate about neuroimaging, please share👇
6
21
67
Pleased to present our paper @eBioMedicine, on the Lumipulse plasma pTau217 assay. Lumipulse-G platform → large global installation base in clinical pathology services → better access/uptake of plasma #ptau217 into clinical practice. Link: https://t.co/dZaIRfJPL2
#Alzheimers
0
2
13
Very proud moment for our lab. Congratulations @vincentDore2
We at Rowe Lab are very proud that our PET expert, @vincentDore2 was awarded the prestigious de Leon Prize, as senior author of “CenTauR: Toward a universal scale and masks for standardizing tau imaging studies”. Time to celebrate this great achievement! #AAIC24 #AIC
3
2
11
Join our team in Melbourne, as a postdoc. You will enjoy working with an imaging expert, @vincentDore2, benefiting from the clinical and research expertise in @RoweLab_aus. Please spread the word and feel free to share the post with your colleagues and final-year PhD students.
Don't miss out on the opportunity to join our team! The final day (21st) to apply for this postdoc position is fast approaching. #AlzheimersDisease #NeuroImaging #BrainScience #AlzheimerResearch #Neuroscience #ClinicalTrials #jobopening #careerdevelopment
0
0
6
🌊🏄♀️ Exciting news! A postdoctoral opportunity is now available in my team in Melbourne! Join us and contribute to cutting-edge research in imaging the aging brain. #postdocopportunity #scienceAustralia 🏖️🐨🦘 https://t.co/OltJIZdnqT
jobs.csiro.au
CSIRO Postdoctoral Fellowship in PET Neuroimaging for Alzheimer's Disease
2
8
12
Trials are currently in progress for #Alzheimer's blood tests in Australia. Tune in to our interview on @7NewsMelbourne to stay informed and contribute to the journey against Alzheimer's. #Alzheimers #Research #Dementia #DementiaAwareness
#ICYMI Professor Chris Rowe, Clinical Lead in the Florey's Dementia Mission, spoke to @7NewsMelbourne about the efficacy of a potential new blood test that can detect early signs of Alzheimer's. In collaboration with @Austin_Health @ADNeT_Australia & @UniMelb
0
3
12
I could not make it to @HAIconference in Miami this year 🫤 but my co-authors from @RoweLab_aus will be kindly presenting my poster 😊. Drop by the board #109 to discuss utility of plasma biomarker, pTau-217, in discriminating Intermediate/Advanced #Alzheimers. #HAI2024
1
0
6
Exciting results!🧠✨Our latest study showcases that plasma P217+tau can distinguish Intermediate or Advanced stage #Alzheimer's, defined based on the 2023 biological PET staging scheme. Dive into the details in our preprint: https://t.co/ngVWhnxF90
#AlzheimersResearch
medrxiv.org
Background Plasma phospho-tau biomarkers, such as p217+tau, excel at identifying Alzheimer’s Disease (AD) neuropathology. However, questions remain regarding their capacity to inform AD biological...
0
2
9
🔥 Hot off the press: Utilizing 18F-AV-133 VMAT2 PET Imaging to Monitor Progressive Nigrostriatal Degeneration in Parkinson Disease #neurology #parkinsons #biomarker #PET #NeuroTwitter
https://t.co/Bw45NFzkqw
1
5
27
Check out the paper by our collaborator, @YingXia87, on changes in basal forebrain in normal aging and Alzheimer’s disease.
🧠 How does the basal forebrain change in normal aging and Alzheimer’s disease? 🧠 Check out our new paper that reveals the patterns of volume loss in the cholinergic system over 14 years in 516 old adults from AIBL. #ENDALZ #Alzheimers
https://t.co/bLEfoc9knv
1
1
2
We’re in dire need of a standardised scale for quantification of tau PET. Drop by the poster by @vincentDore2 at site 361 to know more about the CenTauR scale. #AAIC2023
0
6
11
How do blood biomarkers compare to amyloid and tau PET in predicting cognitive decline? Drop by poster 252 at #AAIC2023 to know more. The full paper can be found here: https://t.co/3fqdi3XKz7
0
1
6
Enjoying day #2 of the #AAIC2023 in Amsterdam with @RoweNeuroSci , @vincentDore2 , @Nat_Krishnadas , @AzadehFeizpour and Marj, but would like to acknowledge the many of our hard-working team members back in Melbourne that are missing from this photo.
0
3
28
To decrease cost of clinical trials, plasma p217+tau is recommended to be used as a 'screening' measure in MCI/mild dementia but works better as a 'pre-screening' measure in cognitively unimpaired. (3/3)
0
0
1
We showed: In MCI/mild dementia, p217+tau predicted cognitive decline with a medium-large effect size; effect size comparable to that for Aβ and tau PET. In cognitively unimpaired, among the three biomarkers, only tau PET predicted 2-year cognitive decline on AIBL-PACC (2/3)
1
0
1
Our paper is finally out on @jpreventionalz1. In this #OpenAccess paper, we have compared plasma p217+tau to Aβ and tau PET to assess their comparative prognostic performance in both cognitively unimpaired and cognitively impaired groups. (1/3) https://t.co/3fqdi3XKz7
#Alzheimers
link.springer.com
The Journal of Prevention of Alzheimer's Disease - Plasma p217+tau has shown high concordance with cerebrospinal fluid (CSF) and positron emission tomography (PET) measures of amyloid-β...
1
1
6